In a phase I exploratory pharmacodynamic study, XL147 has been assessed in combination with XL765 (Voxtalisib, a dual PI3K/mTOR inhibitor) in patients with GBM relapses before surgical resection. This evidence concerns the gene PIK3CD and glioblastoma.